Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 2Phase 4 1

Status

Completed 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Hematologic Neoplasms 2COVID-19 2Respiratory Sounds 1Pharmacokinetics 1Neoplasms 1Lymphoma, Follicular 1Crohn Disease 1Bronchiolitis Obliterans Syndrome 1Asthma 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Azithromycin × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05599347 2025-04-04

AZITRATIM

Rambam Health Care Campus

Phase 2 Recruiting
180 enrolled

Crohn Disease

NCT02517099 2023-03-06

PrIGMa

Imperial College London

Phase 2 Completed
60 enrolled 10 charts
Lymphoid

Asthma, Lymphoma, Follicular, Respiratory Sounds

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

NCT04341207 2020-04-10

ONCOVID

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown
1,000 enrolled

COVID-19, Neoplasms

NCT00644176 2011-06-08

A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

Pfizer

Phase 2 Completed
66 enrolled

Pharmacokinetics

Data powered by HemOnc (CC BY 4.0) Colophon ⚡